The Nuclear Receptor, RORγ, Regulates Pathways Necessary for Breast Cancer Metastasis

EBioMedicine

Volumn 6, Issue , 2016, Pages 59-72

  Oh, Tae Gyu ^a   Wang, Shu Ching M ^a   Acharya, Bipul R ^a   Goode, Joel M ^a   Graham, J Dinny ^b   Clarke, Christine L ^b   Yap, Alpha S ^a   Muscat, George E O ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Breast cancer; Carcinogenesis; DNA repair; EMT (epithelial mesenchymal transition); MaSC (mammary stem cell); Metastasis; Nuclear receptor; RNA seq; ROR (RORC, RORgamma); Stemness; TGF (TGF beta)

Indexed keywords

CELL NUCLEUS RECEPTOR; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SCATTER FACTOR RECEPTOR; SMAD PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; 1,1,1,3,3,3-HEXAFLUORO-2-(2-FLUORO-4'-((4-(PYRIDIN-4-YLMETHYL)PIPERAZIN-1-YL)METHYL)-(1,1'-BIPHENYL)-4-YL)PROPAN-2-OL; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROPANOL; RORC PROTEIN, HUMAN; SR 1078;

ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; BREAST METASTASIS; CELL MIGRATION ASSAY; CELL VIABILITY ASSAY; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA LIBRARY; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; NEXT GENERATION SEQUENCING; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; SURVIVAL RATE; WESTERN BLOTTING; BREAST TUMOR; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GENETICS; MCF-7 CELL LINE; METASTASIS; PATHOLOGY; SEQUENCE ANALYSIS; TUMOR CELL LINE;

BENZAMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DNA REPAIR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NEOPLASM METASTASIS; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; PIPERAZINES; PROPANOLS; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84959421534     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.02.028     Document Type: Article

References (56)

1. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. 2003, 100:3983-3988.
2. Anastassiou D., Rumjantseva V., Cheng W., Huang J., Canoll P.D., Yamashiro D.J., Kandel J.J. Human cancer cells express slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer 2011, 11:529.
3. Anders S., Pyl P.T., Huber W. HTSeq-a python framework to work with high-throughput sequencing data. Bioinformatics (Oxf., Engl.) 2015, 31:166-169.
4. Carter L., Moisan J., Majchrzak K., Hu X., Morgan R., Liu X., Demock K., Wang Y., Lesch C., Sanchez B. Novel RORgamma agonists enhance anti-tumor activity of adoptive T cell therapy (TUM2P. 1010). J. Immunol. 2015, 194:69.67.
5. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 2008, 7:504-516.
6. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4434.
7. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., Viale G., Delorenzi M., Zhang Y., d'Assignies M.S. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 2007, 13:3207-3214.
8. Doan T.B., Eriksson N.A., Graham D., Funder J.W., Simpson E.R., Kuczek E.S., Clyne C., Leedman P.J., Tilley W.D., Fuller P.J., et al. Breast cancer prognosis predicted by nuclear receptor-coregulator networks. Mol. Oncol. 2014.
9. Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T.R. STAR: ultrafast universal RNA-seq aligner. Bioinformatics (Oxf., Engl.) 2013, 29:15-21.
10. Dowhan D.H., Harrison M.J., Eriksson N.A., Bailey P., Pearen M.A., Fuller P.J., Funder J.W., Simpson E.R., Leedman P.J., Tilley W.D., et al. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocrinol. Relat. Cancer 2012, 19:509-526.
11. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 2007, 608:1-22.
12. Guo W., Keckesova Z., Donaher J.L., Shibue T., Tischler V., Reinhardt F., Itzkovitz S., Noske A., Zurrer-Hardi U., Bell G., et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012, 148:1015-1028.
13. Györffy B., Lanczky A., Eklund A.C., Denkert C., Budczies J., Li Q., Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 2010, 123:725-731.
14. Harrell J.C., Prat A., Parker J.S., Fan C., He X., Carey L., Anders C., Ewend M., Perou C.M. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res. Treat. 2012, 132:523-535.
15. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., Fridlyand J., Sahin A., Agarwal R., Joy C., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009, 69:4116-4124.
16. Holland J.D., Gyorffy B., Vogel R., Eckert K., Valenti G., Fang L., Lohneis P., Elezkurtaj S., Ziebold U., Birchmeier W. Combined wnt/beta-catenin, met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Rep. 2013, 5:1214-1227.
17. Hu X., Wang Y., Hao L.Y., Liu X., Lesch C.A., Sanchez B.M., Wendling J.M., Morgan R.W., Aicher T.D., Carter L.L., et al. Sterol metabolism controls T(H)17 differentiation by generating endogenous RORgamma agonists. Nat. Chem. Biol. 2015, 11:141-147.
18. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
19. Kittler R., Zhou J., Hua S., Ma L., Liu Y., Pendleton E., Cheng C., Gerstein M., White K.P. A comprehensive nuclear receptor network for breast cancer cells. Cell Rep. 2013, 3:538-551.
20. Krämer A., Green J., Pollard J., Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics (Oxf., Engl.) 2014, 30:523-530.
21. Kumar N., Lyda B., Chang M.R., Lauer J.L., Solt L.A., Burris T.P., Kamenecka T.M., Griffin P.R. Identification of SR2211: a potent synthetic RORgamma-selective modulator. ACS Chem. Biol. 2012, 7:672-677.
22. Lekva T., Berg J.P., Heck A., Fougner S.L., Olstad O.K., Ringstad G., Bollerslev J., Ueland T. Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery. PLoS One 2013, 8.
23. Li J., Han L., Roebuck P., Diao L., Liu L., Yuan Y., Weinstein J.N., Liang H. TANRIC: an interactive open platform to explore the function of lncRNAs in Cancer. Cancer Res. 2015, 75:3728-3737.
24. Liberzon A., Subramanian A., Pinchback R., Thorvaldsdottir H., Tamayo P., Mesirov J.P. Molecular signatures database (MSigDB) 3.0. Bioinformatics (Oxf., Engl.) 2011, 27:1739-1740.
25. Lim E., Wu D., Pal B., Bouras T., Asselin-Labat M.L., Vaillant F., Yagita H., Lindeman G.J., Smyth G.K., Visvader J.E. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 2010, 12:R21.
26. Lo P.K., Kanojia D., Liu X., Singh U.P., Berger F.G., Wang Q., Chen H. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFbeta signaling. Oncogene 2012, 31:2614-2626.
27. Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014, 15:550.
28. McLean C.Y., Bristor D., Hiller M., Clarke S.L., Schaar B.T., Lowe C.B., Wenger A.M., Bejerano G. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 2010, 28:495-501.
29. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. 2005, 102:13550-13555.
30. Mote P.A., Balleine R.L., McGowan E.M., Clarke C.L. Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J. Clin. Endocrinol. Metab. 1999, 84:2963-2971.
31. Muscat G.E., Eriksson N.A., Byth K., Loi S., Graham D., Jindal S., Davis M.J., Clyne C., Funder J.W., Simpson E.R., et al. Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol. Endocrinol. 2013, 27:350-365.
32. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
33. Oh T.G., Bailey P., Dray E., Smith A.G., Goode J., Eriksson N., Funder J.W., Fuller P.J., Simpson E.R., Tilley W.D., et al. PRMT2 and RORgamma expression are associated with breast cancer survival outcomes. Mol. Endocrinol. 2014, 28:1166-1185.
34. Ørom U.A., Derrien T., Beringer M., Gumireddy K., Gardini A., Bussotti G., Lai F., Zytnicki M., Notredame C., Huang Q., et al. Long noncoding RNAs with enhancer-like function in human cells. Cell 2010, 143:46-58.
35. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
36. Pomp V., Leo C., Mauracher A., Korol D., Guo W., Varga Z. Differential expression of epithelial-mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer. Breast Cancer Res. Treat. 2015.
37. Ponzo M.G., Lesurf R., Petkiewicz S., O'Malley F.P., Pinnaduwage D., Andrulis I.L., Bull S.B., Chughtai N., Zuo D., Souleimanova M., et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc. Natl. Acad. Sci. 2009, 106:12903-12908.
38. Ringner M., Fredlund E., Hakkinen J., Borg A., Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One 2011, 6:e17911.
39. Scheel C., Eaton E.N., Li S.H., Chaffer C.L., Reinhardt F., Kah K.J., Bell G., Guo W., Rubin J., Richardson A.L., et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
40. Schmidt M., Böhm D., von Törne C., Steiner E., Puhl A., Pilch H., Lehr H.-A., Hengstler J.G., Kölbl H., Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast Cancer. Cancer Res. 2008, 68:5405-5413.
41. Shi Z., Wang J., Zhang B. NetGestalt: integrating multidimensional omics data over biological networks. Nat. Methods 2013, 10:597-598.
42. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
43. Smith M.C., Luker K.E., Garbow J.R., Prior J.L., Jackson E., Piwnica-Worms D., Luker G.D. CXCR4 regulates growth of both primary and metastatic breast Cancer. Cancer Res. 2004, 64:8604-8612.
44. Solt L.A., Kumar N., Nuhant P., Wang Y., Lauer J.L., Liu J., Istrate M.A., Kamenecka T.M., Roush W.R., Vidovic D., et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011, 472:491-494.
45. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 2006, 98:262-272.
46. Su X., Malouf G.G., Chen Y., Zhang J., Yao H., Valero V., Weinstein J.N., Spano J.P., Meric-Bernstam F., Khayat D., et al. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget 2014, 5:9864-9876.
47. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 2005, 102:15545-15550.
48. Todaro M., Gaggianesi M., Catalano V., Benfante A., Iovino F., Biffoni M., Apuzzo T., Sperduti I., Volpe S., Cocorullo G., et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 2014, 14:342-356.
49. van't Veer L.J., Dai H., Van De Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
50. Wang Y., Kumar N., Nuhant P., Cameron M.D., Istrate M.A., Roush W.R., Griffin P.R., Burris T.P. Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORalpha and RORgamma. ACS Chem. Biol. 2010, 5:1029-1034.
51. Yang C., McDonald J.G., Patel A., Zhang Y., Umetani M., Xu F., Westover E.J., Covey D.F., Mangelsdorf D.J., Cohen J.C., et al. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J. Biol. Chem. 2006, 281:27816-27826.
52. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., Ma L., Shah B., Panopoulos A.D., Schluns K.S., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28:29-39.
53. Yang L., Lin C., Jin C., Yang J.C., Tanasa B., Li W., Merkurjev D., Ohgi K.A., Meng D., Zhang J., et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013, 500:598-602.
54. Ye X., Tam W.L., Shibue T., Kaygusuz Y., Reinhardt F., Ng Eaton E., Weinberg R.A. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 2015, 525:256-260.
55. Zou W., Restifo N.P. TH17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 2010, 10:248-256.
56. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., Koudriakova T.B., Alton G., Cui J.J., Kung P.P., et al. An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67:4408-4417.